Antimicrobial therapies for Q fever

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 11, 2013, Pages 1207-1214

  Kersh, Gilbert J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antibacterial agents; Coxiella burnetii; disease management; doxycycline; pregnancy; Q fever

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL DNA; BACTERIUM ANTIBODY; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLOROQUINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; HYDROXYCHLOROQUINE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; TELITHROMYCIN;

ALLERGIC REACTION; ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; COXIELLA BURNETII; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PREGNANCY; Q FEVER; RECOMMENDED DRUG DOSE; REVIEW; SEROLOGY; VALVULAR HEART DISEASE;

ANTI-INFECTIVE AGENTS; COXIELLA BURNETII; DOXYCYCLINE; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; Q FEVER; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84888350104     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.840534     Document Type: Review

References (65)

1. McQuiston JH, Childs JE. Q fever in humans and animals in the United States. Vector Borne Zoonotic Dis. 2(3), 179-191 (2002
2. Hatchette T, Campbell N, Hudson R, Raoult D, Marrie TJ. Natural history of Q fever in goats. Vector Borne Zoonotic Dis. 3(1), 11-15 (2003
3. van der Hoek W, Dijkstra F, Schimmer B et al. Q fever in the Netherlands: An update on the epidemiology and control measures. Euro Surveill. 15(12), pii: 19520 (2010
4. Graham JG, MacDonald LJ, Hussain SK, Sharma UM, Kurten RC, Voth DE. Virulent Coxiella burnetii pathotypes productively infect primary human alveolar macrophages. Cell. Microbiol. 15(6), 1012-1025 (2013
5. Voth DE, Heinzen RA. Lounging in a lysosome: The intracellular lifestyle of Coxiella burnetii. Cell. Microbiol. 9(4), 829-840 (2007
6. Benenson AS, Tigertt WD. Studies on Q fever in man. Trans. Assoc. Am. Physicians 69, 98-104 (1956). The very low infectious dose of C. burnetii for humans via inhalation of aerosols is defined in this study
7. Dupuis G, Petite J, Peter O, Vouilloz M. An important outbreak of human Q fever in a Swiss Alpine valley. Int. J. Epidemiol. 16(2), 282-287 (1987
8. Maurin M, Raoult D. Q fever. Clin. Microbiol. Rev. 12(4), 518-553 (1999
9. Clark WH, Lennette EH. Treatment of Q fever with antibiotics. Ann. NY Acad. Sci. 55(6), 1004-1018 (1952
10. Marrie TJ. Acute Q fever. In: Q Fever vol. 1. The disease. Marrie TJ (Ed.). CRC Press, Boca Raton, FL, 125-160 (1990
11. Botelho-Nevers E, Fournier PE, Richet H et al. Coxiella burnetii infection of aortic aneurysms or vascular grafts: Report of 30 new cases and evaluation of outcome. Eur. J. Clin. Microbiol. Infect. Dis. 26(9), 635-640 (2007
12. Fournier PE, Casalta JP, Piquet P, Tournigand P, Branchereau A, Raoult D. Coxiella burnetii infection of aneurysms or vascular grafts: Report of seven cases and review. Clin. Infect. Dis. 26(1), 116-121 (1998
13. Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D. Risks factors and prevention of Q fever endocarditis. Clin. Infect. Dis. 33(3), 312-316 (2001
14. Kampschreur LM, Dekker S, Hagenaars JC et al. Identification of risk factors for chronic Q fever, the Netherlands. Emerg. Infect. Dis. 18(4), 563-570 (2012
15. Ellis ME, Smith CC, Moffat MA. Chronic or fatal Q-fever infection: A review of patients seen in North-East Scotland (1967-80). Q. J. Med. 52(205), 54-66 (1983
16. Jover-Diaz F, Robert-Gates J, Andreu-Gimenez L, Merino-Sanchez J. Q fever during pregnancy: An emerging cause of prematurity and abortion. Infect. Dis. Obstetr. Gynecol. 9(1), 47-49 (2001
17. Langley JM, Marrie TJ, Leblanc JC, Almudevar A, Resch L, Raoult D. Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes. Am. J. Obstetr. Gynecol. 189(1), 228-232 (2003
18. Stein A, Raoult D. Q fever during pregnancy: A public health problem in southern France. Clin. Infect. Dis. 27(3), 592-596 (1998
19. Raoult D, Fenollar F, Stein A. Q fever during pregnancy: Diagnosis, treatment, and follow-up. Arch. Intern. Med. 162(6), 701-704 (2002
20. Raoult D, Stein A. Q fever during pregnancy-a risk for women, fetuses, and obstetricians. N. Engl. J. Med. 330(5), 371 (1994
21. Schneeberger PM, Hermans MH, van Hannen EJ, Schellekens JJ, Leenders AC, Wever PC. Real-time PCR with serum samples is indispensable for early diagnosis of acute Q fever. Clin. Vaccine Immunol. 17(2), 286-290 (2010
22. Stoker MG, Fiset P. Phase variation of the Nine Mile and other strains of Rickettsia burneti. Can. J. Microbiol. 2(3), 310-321 (1956
23. CDC. Diagnosis and management of Q Fever - United States, 2013: Recommendations from CDC and the Q Fever working group. MMWR Morb. Mortal. Wkly Rep. 62(RR03), 1-23 (2013
24. Teunis PF, Schimmer B, Notermans DW et al. Time-course of antibody responses against Coxiella burnetii following acute Qfever. Epidemiol. Infect. 141(1), 62-73 (2013
25. Wegdam-Blans MC, Kampschreur LM, Delsing CE et al. Chronic Q fever: Review of the literature and a proposal of new diagnostic criteria. J. Infect. 64(3), 247-259 (2012
26. Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob. Agents chemother. 45(12), 3644-3646 (2001
27. Sobradillo V, Zalacain R, Capelastegui A, Uresandi F, Corral J. Antibiotic treatment in pneumonia due to Q fever. Thorax 47(4), 276-278 (1992
28. Million M, Thuny F, Richet H, Raoult D. Long-term outcome of Q fever endocarditis: A 26-year personal survey. Lancet Infect. Dis. 10(8), 527-535 (2010
29. Levy PY, Drancourt M, Etienne J et al. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. Antimicrob. Agents chemother. 35(3), 533-537 (1991
30. Lam C, Mathison GE. Effect of low intraphagolysosomal pH on antimicrobial activity of antibiotics against ingested staphylococci. J. Med. Microbiol. 16(3), 309-316 (1983
31. Raoult D, Drancourt M, Vestris G. Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob. Agents Chemother. 34(8), 1512-1514 (1990
32. Maurin M, Benoliel AM, Bongrand P, Raoult D. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: The Coxiella burnetii paradigm. J. Infect. Dis. 166(5), 1097-1102 (1992
33. Raoult D, Houpikian P, Tissot Dupont H, Riss JM, Arditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: Comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch. Intern. Med. 159(2), 167-173 (1999
34. Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D́Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob. Agents Chemother. 56(1), 70-74 (2012
35. Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K. Interference of iron with the absorption of tetracyclines in man. Br. Med. J. 4(5734), 532-534 (1970
36. Lecaillet A, Mallet MN, Raoult D, Rolain JM. Therapeutic impact of the correlation of doxycycline serum concentrations and the decline of phase I antibodies in Q fever endocarditis. J. Antimicrob. Chemother. 63(4), 771-774 (2009
37. Drucker AM, Rosen CF. Drug-induced photosensitivity: Culprit drugs, management and prevention. Drug saf. 34(10), 821-837 (2011
38. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin. Ophthalmol. 23(3), 201-209 (2008
39. Maltezou HC, Constantopoulou I, Kallergi C et al. Q fever in children in Greece. Am. J. Trop. Med. Hyg. 70(5), 540-544 (2004
40. Roest HJ, van Gelderen B, Dinkla A et al. Q fever in pregnant goats: Pathogenesis and excretion of Coxiella burnetii. PLoS ONE 7(11), e48949 (2012
41. Boden K, Brueckmann A, Wagner-Wiening C et al. Maternofetal consequences of Coxiella burnetii infection in pregnancy: A case series of two outbreaks. BMC Infect. Dis. 12, 359 (2012). An examination of pregnant women with Q fever who found no fetal complications associated with Q fever during pregnancy
42. van der Hoek W, Meekelenkamp JC, Leenders AC, WijersN, NotermansDW, Hukkelhoven CW. Antibodies against Coxiella burnetii and pregnancy outcome during the 2007-2008 Q fever outbreaks in The Netherlands. BMC Infect. Dis. 11, 44 (2011). Pregnant women with antibodies against C. burnetii had similar pregnancy outcomes compared with women without C. burnetii antibodies
43. Madariaga MG, Rezai K, Trenholme GM, Weinstein RA. Q fever: A biological weapon in your backyard. Lancet Infect. Dis. 3(11), 709-721 (2003
44. Pittman PR, Norris SL, Coonan KM, McKee KT Jr. An assessment of health status among medical research volunteers who served in the Project Whitecoat program at Fort Detrick, Maryland. Mil. Med. 170(3), 183-187 (2005
45. Omsland A, Beare PA, Hill J et al. Isolation from animal tissue and genetic transformation of Coxiella burnetii are facilitated by an improved axenic growth medium. Appl. Environ. Microbiol. 77(11), 3720-3725 (2011
46. Rolain JM, Lambert F, Raoult D. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline. Ann. NY Acad. Sci. 1063, 252-256 (2005
47. Rouli L, Rolain JM, El Filali A, Robert C, Raoult D. Genome sequence of Coxiella burnetii 109, a doxycycline-resistant clinical isolate. J. Bacteriol. 194(24), 6939 (2012
48. Brennan RE, Samuel JE. Evaluation of Coxiella burnetii antibiotic susceptibilities by real-time PCR assay. J. Clin. Microbiol. 41(5), 1869-1874 (2003
49. Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A. Managing Q fever during pregnancy: The benefits of long-term cotrimoxazole therapy. Clin. Infect. Dis. 45(5), 548-555 (2007). This study found fetal complications associated with Q fever during pregnancy that could be alleviated by 5-week course of co-trimoxazole
50. Angelakis E, Million M, D́Amato F et al. Q fever and pregnancy: Disease, prevention, and strain specificity. Eur. J. Clin. Microbiol. Infect. Dis. 32(3), 361-368 (2013
51. Yeaman MR, Mitscher LA, Baca OG. In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob. Agents Chemother. 31(7), 1079-1084 (1987
52. Lever MS, Bewley KR, Dowsett B, Lloyd G. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. Int. J. Antimicrob. Agents 24(2), 194-196 (2004
53. Gikas A, Spyridaki I, Scoulica E, Psaroulaki A, Tselentis Y. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. Antimicrob. Agents Chemother. 45(11), 3276-3278 (2001
54. Gikas A, Spyridaki I, Psaroulaki A, Kofterithis D, Tselentis Y. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob. Agents Chemother. 42(10), 2747-2748 (1998
55. Raoult D, Yeaman MR, Baca OG. Susceptibility of Coxiella burnetii to pefloxacin and ofloxacin in ovo and in persistently infected L929 cells. Antimicrob. Agents Chemother. 33(5), 621-623 (1989
56. Rolain JM, Maurin M, Raoult D. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob. Agents Chemother. 45(1), 301-302 (2001
57. Raoult D, Torres H, Drancourt M. Shell-vial assay: Evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Antimicrob. Agents Chemother. 35(10), 2070-2077 (1991
58. Bental T, Fejgin M, Keysary A et al. Chronic Q fever of pregnancy presenting as Coxiella burnetii placentitis: Successful outcome following therapy with erythromycin and rifampin. Clin. Infect. Dis. 21(5), 1318-1321 (1995
59. Hellmeyer L, Schmitz-Ziegler G, Slenczka W, Schmidt S. [Q Fever in pregnancy: A case report and review of the literature]. Z. Geburtshilfe Neonatol. 206(5), 193-198 (2002
60. Keysary A, Itzhaki A, Rubinstein E, Oron C, Keren G. The in-vitro anti-rickettsial activity of macrolides. J. Antimicrob. Chemother. 38(4), 727-731 (1996
61. Perez-del-Molino A, Aguado JM, Riancho JA, Sampedro I, Matorras P, Gonzalez-Macias J. Erythromycin and the treatment of Coxiella burnetii pneumonia. J. Antimicrob. Chemother. 28(3), 455-459 (1991
62. Anderson AD, Kruszon-Moran D, Loftis AD et al. Seroprevalence of Q fever in the United States, 2003-2004. Am. J. Trop. Med. Hyg. 81(4), 691-694 (2009
63. Prabhu M, Nicholson WL, Roche AJ et al. Q fever, spotted fever group, and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania. Clin. Infect. Dis. 53(4), e8-15 (2011
64. Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute q Fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. Clin. Infect. Dis. 57(6), 836-844 (2013
65. Kampschreur LM, Oosterheert JJ, Hoepelman AI et al. Prevalence of chronic Q fever in patients with a history of cardiac valve surgery in an area where Coxiella burnetii is epidemic. Clin. Vaccine immunol. 19(8), 1165-1169 (2012